Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2493${count})

  • MJFF Research Grant, 2013
    Development of G2019S Selective LRRK2 Inhibitors for the Treatment of Parkinson’s Disease

    Objective/Rationale:             
    The LRRK2 kinase has been implicated as a potential therapeutic target for the treatment of Parkinson’s disease (PD). The goal of this project is to make experimental...

  • Rapid Response Innovation Awards, 2013
    Evaluation of Targeted Plasticity Therapy as a Treatment for Motor Dysfunction in Parkinson’s Disease

    Objective/Rationale:             

    Deterioration of motor function is a debilitating symptom of Parkinson’s disease (PD). We have recently developed a novel method that utilizes stimulation of the...

  • Understanding LRRK2 Biology, 2010
    Biochemical characterization of full length human recombinant LRRK1 and LRRK2

    Promising Outcomes of Original Grant:
    In our initial application we proposed to take advantage of a lentiviral system recently developed in KULeuven to express full-length, soluble human LRRK1 and...

  • Research Grant, 2010
    Longitudinal Follow-Up of Clinical and Neuroimaging Signs and Biomarkers in Symptoms & Side Effects and aSymptoms & Side Effects LRRK2 Mutation Carriers in Comparison to Idiopathic PD and Controls

    Objective/Rationale
    Parkinson’s disease (PD) is a common neurodegenerative disease that leads to progressive motor impairment as well as autonomic and cognitive disturbances. The cause of most of...

  • MJFF Research Grant, 2010
    LRRK2 G2019S Disease Penetrance Modifiers

    Objective/Rationale: 
    The most commonly found mutation in Parkinson’s disease patients is LRRK2 G2019S.  This mutation can lead to the development of Parkinson’s disease at very different ages, from...

  • MJFF Research Grant, 2010
    Characterization of an Inhibitor Compound of LRRK2 Function

    Objective/Rationale: 
    LRRK2 (Leucine-Rich Repeat Kinase 2) is a protein thought to be involved in regulating signaling pathways in cells. Mutations in the gene for LRRK2 are associated with some...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.